<DOC>
	<DOC>NCT01114217</DOC>
	<brief_summary>To evaluate the safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia (IDA).</brief_summary>
	<brief_title>Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Key Inclusion Criteria include: 1. Subjects who completed participation in study AMAGFERIDA301 2. Female subjects of childbearing potential who are sexually active must be on an effective method of birth control and agree to remain on birth control until completion of participation in the study Key Exclusion Criteria include: 1. Experienced a serious adverse event (SAE) related to ferumoxytol in study AMAGFERIDA301 2. Female subjects who are pregnant, intend to become pregnant, are breastfeeding, or have a positive serum/urine pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Iron deficiency anemia</keyword>
	<keyword>Feraheme</keyword>
	<keyword>ferumoxytol</keyword>
	<keyword>AUB</keyword>
	<keyword>cancer</keyword>
	<keyword>GI disorders</keyword>
	<keyword>postpartum anemia</keyword>
	<keyword>The treatment of iron deficiency anemia (IDA)</keyword>
</DOC>